HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulation Of US Supplement Industry Needs ‘Really Hard Look’ – FDA's Woodcock

Executive Summary

Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.

You may also be interested in...



As US FDA’s Principal Deputy Commissioner, Woodcock Focusing On Food Issues

Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.

US Supplement Industry Capitol Hill Champion, Pivotal Drug Legislation Author Orrin Hatch Dies

DSHEA, legislation Congress passed in 1994 establishing framework for FDA’s oversight of supplement manufacturing and marketing, doesn’t bear Hatch’s name. But in US consumer health products industry, his name is probably more frequently linked with DSHEA than with pivotal drug legislation he co-authored.

VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question

In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel